Investigation Launched into BioSig Technologies and Streamex Merger

Categories: Louisiana Business NewsLouisiana HealthcareLouisiana ManufacturingLouisiana News

Legal scrutiny on BioSig Technologies' merger with Streamex Exchange Corporation

News Summary

Kahn Swick & Foti, LLC is investigating the proposed merger between BioSig Technologies and Streamex Exchange Corporation to assess fairness for BioSig shareholders. Led by former Louisiana Attorney General Charles C. Foti, Jr., the inquiry aims to evaluate the merger process and ensure equitable terms for existing shareholders. Shareholders are encouraged to discuss their legal rights with KSF. Other law firms are also scrutinizing the deal, raising concerns over investment impacts. The investigation could have significant implications for BioSig’s future integration with Streamex.

New Orleans, LA – Kahn Swick & Foti, LLC (KSF) is currently investigating the proposed merger between BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. This investigation is spearheaded by former Louisiana Attorney General Charles C. Foti, Jr., Esq., who leads the firm in assessing whether the merger is fair to the shareholders of BioSig Technologies.

The inquiry is focused on the adequacy of the merger process and aims to determine if the terms of the merger are equitable for existing shareholders. The proposed transaction will result in BioSig shareholders and holders of common stock equivalents owning 25% of the fully diluted common stock of BioSig following the completion of the merger.

In light of the investigation, KSF is actively reaching out to shareholders to discuss their legal rights related to this merger. Shareholders are encouraged to connect with KSF Managing Partner Lewis S. Kahn for further information or to express any concerns they may have regarding the merger. Interested parties can reach out via email or call the firm toll-free for assistance.

More details regarding the investigation are available on KSF’s specific webpage dedicated to the BioSig Technologies case. This resource aims to keep shareholders informed and engaged with the ongoing examination of the merger.

Sharing similar concerns, other law firms, including Monteverde & Associates PC, are also conducting investigations into the merger, highlighting a broader scrutiny from legal experts regarding the fairness of the deal for investors. KSF emphasizes that participation in discussions is welcomed without any obligation or cost to the shareholders, making the inquiry accessible to all interested parties.

As part of its operations, Kahn Swick & Foti, LLC is renowned for its expertise in national securities and class-action litigation, lending credibility to their examination of the BioSig Technologies merger. The firm is known for ensuring that shareholder rights are protected, and it encourages those who might feel affected by the merger to inquire further into their legal options.

This investigation emerges as BioSig Technologies aims to integrate successfully with Streamex Exchange Corporation, prompting a closer look at how such mergers impact the financial landscape and shareholder equity. The results of this inquiry could bring significant implications for BioSig shareholders and shape how similar future mergers are perceived in terms of fairness and legality.

As events continue to unfold, stakeholders in BioSig Technologies and the broader investment community will be closely watching to see how KSF’s investigation develops and the potential findings regarding the merger’s adequacy.

For those looking for more information or wishing to discuss legal rights in relation to the merger, KSF encourages shareholders to take action and reach out to their office.